Document is current
Any future updates will be listed below
-
Authors
Ikenaga, Chiseko
Findlay, Andrew R.
Seiffert, Michelle
Peck, Allison
Peck, Nathan
Johnson, Nicholas E.
Statland, Jeffrey M.
Weihl, Conrad C.
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24AR073317, K08AR075894)
- License Information
-
More Information
Article History
Received: 24 June 2020
Accepted: 22 September 2020
First Online: 29 September 2020
Ethics approval and consent to participate
: This study was approved by the Human studies review committee at Washington University School of Medicine in St. Louis (201903027 for patient meeting, 202005191 for analysis of registry data). All the answers of the questionnaire were deidentified and permitted by the participants to use in this study.
: Not applicable.
: CI, ARF, MS, AP, and, NP declare that they have no competing interests. NEJ receives royalties from the CCMDHI and the CMTHI. He receives research funds from Dyne, AveXis, CSL Behring, Vertex Pharmaceuticals, Fulcrum Therapeutics, ML Bio, Sarepta, and Acceleron Pharma. He has provided consultation for AveXis, AMO Pharma, Strongbridge BioPharma, Acceleron Pharma, Fulcrum Therapeutics, Dyne, Avidity, and Vertex Pharmaceuticals. JMS reports grants and personal fees from Muscular Distrophy Association, FSHD Society, Friends of FSH Research, Dyne, Avidity, Fulcrum, Acceleron, Sarepta, Strongbridge, Genzyme, and PTC. CCW reports grants and personal fees from Sarepta, personal fees from Acceleron, Casma therapeutics, and ML Bio.
